B. Riley raised the firm’s price target on Cytokinetics (CYTK) to $80 from $74 and keeps a Buy rating on the shares. Cytokinetics is among the firm’s top ideas heading into year-end aficamten FDA approval. Management reported positive feedback a from late-cycle FDA meeting focused on final implementation details, with no additional language requests, which ultimately supports the potential for a differentiated REMS program as part of the initial label grant and risk mitigation profile, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CYTK:
- Cytokinetics’ Strategic Financial Maneuvers and Regulatory Advancements Justify Buy Rating
- Cytokinetics Faces Lawsuit Over Misleading Investors
- Morning Movers: Workday surges after Elliot stake, stock buyback program
- Cautious Outlook on Cytokinetics: Hold Rating Amid Competitive Challenges and Uncertain Commercial Impact
- Cytokinetics Discusses Aficamten with FDA in Late Cycle Meeting